Press release
Onyx Scientific grow solid-state polymorph and crystallization chemistry services.
Following a major round of capital expenditure, the UK based contract research organisation, Onyx Scientific Ltd, is pleased to announce the rapid growth of its highly successful solid-state, polymorph screening chemistry services, launched in 2008. Equipped with the latest X-Ray Powder Diffraction and Raman Spectroscopy instrumentation, for automated 96 well format sample preparation, this new solid-state laboratory positions Onyx-Scientific as a preferred outsourcing provider for rapid, solid-form polymorph investigation, salt selection and crystallization studies; and complements Onyx Scientifics’ world-class chemical services, which include: custom synthesis, process development, lead optimization and GMP synthesis and scale up.Onyx Scientific - with its enviable reputation for multi-step, difficult to produce chemistry - conducts problem solving with unparalleled expertise. The Onyx service model provides both dedicated FTE and fee-for-service resource, with full transparency and flexibility to switch resource on and off as needed and at short notice.
Dr Tony Flinn, CEO Onyx Scientific comments, “the pharmaceutical industry will increasingly align with trusted outsourcing partners for solid-state and custom synthesis services to reduce costs, risks and time-to-market. Squeezed by escalating R&D costs, the industry will accelerate its strategy to outsource non-core chemistry services and will no longer use contract services simply as a tactic to overcome near-term capacity shortage. Following our expansion to offer solid-state services, we are witnessing, first-hand, the accelerated trend within large pharma and biotechs to form sustainable outsourcing partnerships”.
Characterized by high risk – just 1 in 20,000 compounds become a pharmaceutical; at a commercial cost of $1 billion; with less than a 50% chance to return investment costs post launch – the industry will increasingly seek to align itself with strategic partners and these relationships will transform the pace and extent to which pharma companies will outsource their R&D and the rigour used to protect IP rights and ownership. Increased productivity, quality results and optimum cost savings will be the collective aim, in order to reap ever greater returns, better use of in-house laboratory space and the removal of capital outlay for hi-tech analytical equipment.
Onyx Scientific has structured its expertise-rich organisation to be creatively involved in the pharmaceutical development process. Without this approach their services would lead to a commodity offering, rather than the opportunity to generate intellectual property. Green chemistry processes also serve to differentiate Onyx in their shared goal to reduce the environmental footprint of the industry.
Recognised as transformational, pharmaceutical outsourcing has taken the industry from its stand-alone company model to a fully integrated pharmaceutical network. Within this model, Onyx Scientific is well placed to provide unmatched chemical services to both the late discovery and early phases of new pharmaceutical development. Uniquely, Onyx successfully combines integrated manufacturing and development capability with solid-state analysis services. This winning combination assures optimal development of new pharmaceutical ingredients and maximum intellectual property return.
Routinely inspected by the MHRA, Onyx Scientifics’ state-of-the-art facility delivers peace-of-mind that all outsourced chemical services comply with Good Manufacturing Practice for the development of Active Pharmaceutical Ingredients (API's).
Onyx Scientifics’ solid-state, polymorph screening expertise provides rapid optimization of the physical polymorphic form of a new compound, its physicochemical properties and bioavailability.
Onyx Scientific highly experienced team of scientists have the expertise and enthusiasm required to meet the exacting demands of the pharmaceutical industry. They are specialists in both lead optimisation, custom synthesis and process development chemistry. 85% of their chemists are PhD qualified and are committed to excellence and rapid problem solving.
Onyx Scientific Ltd
Silverbriar
Enterprise Park East
Sunderland
SR5 2TQ, UK
Tel: +44 191 516 6516
www.onyx-scientific.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Onyx Scientific grow solid-state polymorph and crystallization chemistry services. here
News-ID: 120388 • Views: …
More Releases from Onyx Scientific Ltd

GMP Synthesis chemistry services organisation, Onyx Scientific, announce increas …
Leading chemistry services organisation, Onyx Scientific Ltd, is pleased to announce an increased demand for its early-phase, GMP synthesis, Investigational New Drug (IND) services for the development of Active Pharmaceutical Ingredients (APIs).
“At Onyx we plan for success by focussing on detail” explains CEO Tony Flinn. “Our service driven systems deliver comprehensive chemical route development, efficient raw materials sourcing, thorough analysis and world-class solid-state characterization. We are recognised as the…

Custom Synthesis chemistry services CRO, Onyx Scientific, hails the success of i …
Onyx Scientific, a trusted global chemistry services CRO and leading provider of high justified intermediates and APIs for both phase I and phase II clinical studies, hails the success of its world-class solid-state polymorph screening services for the increased demand for its international GMP-compliant Process Development capability.
Onyx Scientific specialise in Medicinal Chemistry, Process Development, Custom Synthesis, GMP synthesis and Scale-up, in addition to a comprehensive range of Analytical and…

Solid-state chemistry services CRO, Onyx Scientific reports increased demand for …
Experts in the provision of solid-state chemistry services for the pharmaceutical and biotech industries, leading global contract research organisation, Onyx Scientific, is delighted to report increased demand in taking candidate compounds from concept through to process development and scale-up of APIs for Phase I and Phase II clinical studies.
“Handling difficult-to-crystallize materials is an art form as well as a science” explains Tony Flinn, CEO, Onyx Scientific. “Inherently complicated, the implications…

GMP synthesis chemistry services CRO, Onyx Scientific, reports increased small s …
Internationally renowned, contract research organisation Onyx Scientific, is pleased to announce the continued growth of its small-scale GMP custom synthesis services for development APIs (Active Pharmaceutical Ingredients)
Commenting on the growing success of its small-scale GMP synthesis services, CEO, Dr Tony Flinn says “our success is due to open communication and a highly responsive scientific team, who are able to lower the cost of a GMP process by…
More Releases for Contract
Contract Lifecycle Management Software Market Overview: Streamlining Contract Pr …
In recent years, the global Contract Lifecycle Management Software Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Contract Lifecycle Management Software Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot…
Contract Lifecycle Management Software Market Overview: Streamlining Contract Pr …
In recent years, the global Contract Lifecycle Management Software Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Contract Lifecycle Management Software Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot…
Contract Farming Market Beyond the Contract: How Consumer Preferences are Reshap …
Contract Farming Market worth $76.07 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Contract Farming Market- (By Crop Type (Cereals (e.g., wheat, rice, maize), Fruits, Vegetables, Oilseeds, Pulses, Others), By Livestock Type (Poultry, Dairy, Swine, Cattle, Aquaculture, Others, By Contracting Parties (Agribusiness firms, Processors, Cooperatives, Exporters, Retailers, Others)), Trends, Industry Competition Analysis,…
Pharmaceutical Contract Manufacturing and Contract Market 2021 | Detailed Report
The Pharmaceutical Contract Manufacturing and Contract research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the Pharmaceutical Contract Manufacturing and Contract research report offers information and thoughtful facts like share, revenue, historical data, and global market share. It also highlights vital aspects like opportunities, driving, product scope, market overview, and driving…
Contract Staffing Company India | Contract Staffing Services Mumbai & Banglore - …
Characterised with stringent legislation, fluctuating demand, a paucity of employable talent and market unpredictability, the modern business landscape offers a convincing rationale to employ a contract workforce in the business. You may not want to compromise on profits when you can adopt a 'just-in-time' strategy to bring the best workforce on-board using a contract staffing approach. With our cutting-edge contract staffing services, you can have all in one shot: An…
Pharmaceutical Contract Manufacturing and Contract Market Size, Share, Developme …
LP INFORMATION offers a latest published report on Pharmaceutical Contract Manufacturing and Contract Market Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Pharmaceutical Contract Manufacturing and Contract market will register a 6.6% CAGR in terms of revenue, the global market size will reach $ 97680 million by 2025, from $…